Recently, the mostly used checkpoint inhibitors (ICIs), which include CTLA-4 and programmed cell death protein 1 (PD-1)/PD-L1 inhibitors acting through reversing the immunological signals from the immunosuppressive tumour microenvironment, have attracted significant attention in OC oncotherapeutics [54]. Here, CD274 is linked to neoplasm.